SRT-015: A Second-Generation ASK1 Inhibitor for Liver Diseases Including NASH
Time: 2:00 pm
day: Day 1 Seminar B Post-Lunch Tracks
Details:
- SRT-015 treatment results in direct inhibition of apoptosis, inflammation and fibrosis in vitro and in vivo
- Liver-selective small molecule efficacious in a chronic, therapeutic DIO-NASH preclinical model and in multiple acute liver models
- Demonstrated safety in Phase 1 clinical trials; ideal single or combination therapy
